A U.S. District Court in Colorado halted a 70% price cap on Amgen’s Enbrel after granting the company a preliminary injunction. The decision came from Judge Daniel Domenico, who said the cap could cause “economic injury” to Amgen. The ruling interrupts state-level implementation of the pricing policy and adds to the legal friction around drug affordability mechanisms. It also signals that courts may scrutinize the economic impact claims underpinning price controls. For manufacturers and payers, the immediate practical effect is continued pricing freedom for Enbrel while the legal process proceeds—potentially shaping how other states draft or defend similar measures.